Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake

Key Points

• International Assets Investment Management LLC increased its Insulet stake by 61,543.8% in the third quarter, ending with 45,000 shares valued at approximately $5.87 million. Several other institutional investors also raised their positions.
• Insulet reported quarterly earnings of $1.66 per share, beating estimates of $1.47, while revenue rose 23.5% year over year to $801.7 million.
• Insulet shares opened at $149.68, well below their 52-week high of $354.88. Analysts’ consensus rating is “Hold”, with an average price target of $186.68 following several recent target cuts and rating downgrades.

International Assets Investment Management LLC grew its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 61,543.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,000 shares of the medical instruments supplier's stock after acquiring an additional 44,927 shares during the quarter. International Assets Investment Management LLC owned about 0.06% of Insulet worth $5,871,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of PODD. Elevation Wealth Partners LLC raised its stake in Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 104 shares during the last quarter. Activest Wealth Management raised its holdings in Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 149 shares during the period. Sound Income Strategies LLC grew its holdings in Insulet by 4,620.0% in the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 231 shares during the period. WPG Advisers LLC raised its stake in shares of Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier's stock worth $35,000 after buying an additional 171 shares during the period. Finally, State of Wyoming lifted its position in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock valued at $60,000 after buying an additional 73 shares in the last quarter.

Insulet Price Performance

Shares of NASDAQ PODD opened at $149.68 on Monday. The company has a market capitalization of $10.38 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.18 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The business has a 50-day moving average of $140.91 and a 200-day moving average of $179.87.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. Insulet's quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PODD. JPMorgan Chase & Co. cut shares of Insulet from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $275.00 to $152.00 in a research report on Thursday, August 6th. Jefferies Financial Group decreased their price target on Insulet from $275.00 to $190.00 and set a "buy" rating for the company in a report on Monday, October 12th. Wall Street Zen lowered shares of Insulet from a "buy" rating to a "hold" rating in a research report on Saturday, October 24th. Canaccord Genuity Group dropped their price objective on shares of Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Finally, BTIG Research lowered shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Insulet presently has a consensus rating of "Hold" and an average price target of $186.68.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.